☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
ARAMIS Study
Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer
January 30, 2020
Orion's Darolutamide Achieves 1EP in P-III ARAMIS study in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
October 25, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.